![Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes | Science Immunology Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes | Science Immunology](https://www.science.org/cms/asset/72ac232b-af13-4ceb-bddf-85437080efb2/keyimage.gif)
Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes | Science Immunology
A Natural Peptide Antigen within the Plasmodium Ribosomal Protein RPL6 Confers Liver TRM Cell-Mediated Immunity against Malaria
![Performance of the currently available DIVA real‐time PCR assays in classical and recombinant lumpy skin disease viruses - Byadovskaya - 2021 - Transboundary and Emerging Diseases - Wiley Online Library Performance of the currently available DIVA real‐time PCR assays in classical and recombinant lumpy skin disease viruses - Byadovskaya - 2021 - Transboundary and Emerging Diseases - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/58d280ab-cab1-4f50-b365-b621a45a465b/tbed.v68.6.cover.jpg?trick=1667145635194)
Performance of the currently available DIVA real‐time PCR assays in classical and recombinant lumpy skin disease viruses - Byadovskaya - 2021 - Transboundary and Emerging Diseases - Wiley Online Library
![Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes | Science Immunology Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes | Science Immunology](https://www.science.org/cms/10.1126/sciimmunol.abq2427/asset/32c5bd76-1661-4029-9267-3ebc0dad8ec7/assets/images/large/sciimmunol.abq2427-f2.jpg)
Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes | Science Immunology
![Potential Use of Exosomes as Diagnostic Biomarkers and in Targeted Drug Delivery: Progress in Clinical and Preclinical Applications | ACS Biomaterials Science & Engineering Potential Use of Exosomes as Diagnostic Biomarkers and in Targeted Drug Delivery: Progress in Clinical and Preclinical Applications | ACS Biomaterials Science & Engineering](https://pubs.acs.org/cms/10.1021/acsbiomaterials.1c00217/asset/images/large/ab1c00217_0007.jpeg)
Potential Use of Exosomes as Diagnostic Biomarkers and in Targeted Drug Delivery: Progress in Clinical and Preclinical Applications | ACS Biomaterials Science & Engineering
![Vaccines | Free Full-Text | Vaccination with Deglycosylated Modified Hemagglutinin Broadly Protects against Influenza Virus Infection in Mice and Ferrets Vaccines | Free Full-Text | Vaccination with Deglycosylated Modified Hemagglutinin Broadly Protects against Influenza Virus Infection in Mice and Ferrets](https://www.mdpi.com/vaccines/vaccines-10-01304/article_deploy/html/images/vaccines-10-01304-g001.png)
Vaccines | Free Full-Text | Vaccination with Deglycosylated Modified Hemagglutinin Broadly Protects against Influenza Virus Infection in Mice and Ferrets
![Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization | Nature Communications Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization | Nature Communications](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41467-021-27063-4/MediaObjects/41467_2021_27063_Fig10_HTML.png)
Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization | Nature Communications
![Frontiers | Immune Profiles Identification by Vaccinomics After MVA Immunization in Randomized Clinical Study Frontiers | Immune Profiles Identification by Vaccinomics After MVA Immunization in Randomized Clinical Study](https://www.frontiersin.org/files/Articles/586124/fimmu-11-586124-HTML-r1/image_m/fimmu-11-586124-g001.jpg)
Frontiers | Immune Profiles Identification by Vaccinomics After MVA Immunization in Randomized Clinical Study
![Vaccines | Free Full-Text | Vaccination with Deglycosylated Modified Hemagglutinin Broadly Protects against Influenza Virus Infection in Mice and Ferrets Vaccines | Free Full-Text | Vaccination with Deglycosylated Modified Hemagglutinin Broadly Protects against Influenza Virus Infection in Mice and Ferrets](https://www.mdpi.com/vaccines/vaccines-10-01304/article_deploy/html/images/vaccines-10-01304-g003.png)
Vaccines | Free Full-Text | Vaccination with Deglycosylated Modified Hemagglutinin Broadly Protects against Influenza Virus Infection in Mice and Ferrets
![Vaccines | Free Full-Text | Assessing the Protective Dose of a Candidate DIVA Vaccine against Classical Swine Fever Vaccines | Free Full-Text | Assessing the Protective Dose of a Candidate DIVA Vaccine against Classical Swine Fever](https://www.mdpi.com/vaccines/vaccines-09-00483/article_deploy/html/images/vaccines-09-00483-g002-550.jpg)
Vaccines | Free Full-Text | Assessing the Protective Dose of a Candidate DIVA Vaccine against Classical Swine Fever
![Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization | Nature Communications Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization | Nature Communications](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41467-021-27063-4/MediaObjects/41467_2021_27063_Fig1_HTML.png)
Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization | Nature Communications
![Refining the approach to vaccines against influenza A viruses with pandemic potential | Future Virology Refining the approach to vaccines against influenza A viruses with pandemic potential | Future Virology](https://www.futuremedicine.com/cms/10.2217/fvl.15.69/asset/images/medium/figure1.gif)
Refining the approach to vaccines against influenza A viruses with pandemic potential | Future Virology
![Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes | Science Immunology Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes | Science Immunology](https://www.science.org/cms/10.1126/sciimmunol.abq2427/asset/7e131952-dbba-47dd-b76a-6b470357ba8a/assets/images/large/sciimmunol.abq2427-f3.jpg)
Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes | Science Immunology
![Vaccines | Free Full-Text | Assessing the Protective Dose of a Candidate DIVA Vaccine against Classical Swine Fever Vaccines | Free Full-Text | Assessing the Protective Dose of a Candidate DIVA Vaccine against Classical Swine Fever](https://www.mdpi.com/vaccines/vaccines-09-00483/article_deploy/html/images/vaccines-09-00483-g004.png)
Vaccines | Free Full-Text | Assessing the Protective Dose of a Candidate DIVA Vaccine against Classical Swine Fever
![Vaccines | Free Full-Text | Vaccination with Deglycosylated Modified Hemagglutinin Broadly Protects against Influenza Virus Infection in Mice and Ferrets Vaccines | Free Full-Text | Vaccination with Deglycosylated Modified Hemagglutinin Broadly Protects against Influenza Virus Infection in Mice and Ferrets](https://www.mdpi.com/vaccines/vaccines-10-01304/article_deploy/html/images/vaccines-10-01304-g004.png)
Vaccines | Free Full-Text | Vaccination with Deglycosylated Modified Hemagglutinin Broadly Protects against Influenza Virus Infection in Mice and Ferrets
![Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization | Nature Communications Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization | Nature Communications](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41467-021-27063-4/MediaObjects/41467_2021_27063_Fig3_HTML.png)
Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization | Nature Communications
![Vaccines | Free Full-Text | Assessing the Protective Dose of a Candidate DIVA Vaccine against Classical Swine Fever Vaccines | Free Full-Text | Assessing the Protective Dose of a Candidate DIVA Vaccine against Classical Swine Fever](https://www.mdpi.com/vaccines/vaccines-09-00483/article_deploy/html/images/vaccines-09-00483-g002.png)
Vaccines | Free Full-Text | Assessing the Protective Dose of a Candidate DIVA Vaccine against Classical Swine Fever
![Frontiers | Development of Recombinant Protein-Based Vaccine Against Classical Swine Fever Virus in Pigs Using Transgenic Nicotiana benthamiana Frontiers | Development of Recombinant Protein-Based Vaccine Against Classical Swine Fever Virus in Pigs Using Transgenic Nicotiana benthamiana](https://www.frontiersin.org/files/Articles/453657/fpls-10-00624-HTML/image_m/fpls-10-00624-g001.jpg)
Frontiers | Development of Recombinant Protein-Based Vaccine Against Classical Swine Fever Virus in Pigs Using Transgenic Nicotiana benthamiana
![Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization | Nature Communications Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization | Nature Communications](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41467-021-27063-4/MediaObjects/41467_2021_27063_Fig7_HTML.png)
Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization | Nature Communications
![Vaccines | Free Full-Text | Assessing the Protective Dose of a Candidate DIVA Vaccine against Classical Swine Fever Vaccines | Free Full-Text | Assessing the Protective Dose of a Candidate DIVA Vaccine against Classical Swine Fever](https://www.mdpi.com/vaccines/vaccines-09-00483/article_deploy/html/images/vaccines-09-00483-g003.png)
Vaccines | Free Full-Text | Assessing the Protective Dose of a Candidate DIVA Vaccine against Classical Swine Fever
![A Natural Peptide Antigen within the Plasmodium Ribosomal Protein RPL6 Confers Liver TRM Cell-Mediated Immunity against Malaria in Mice - ScienceDirect A Natural Peptide Antigen within the Plasmodium Ribosomal Protein RPL6 Confers Liver TRM Cell-Mediated Immunity against Malaria in Mice - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1931312820302377-fx1.jpg)
A Natural Peptide Antigen within the Plasmodium Ribosomal Protein RPL6 Confers Liver TRM Cell-Mediated Immunity against Malaria in Mice - ScienceDirect
![Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization | Nature Communications Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization | Nature Communications](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41467-021-27063-4/MediaObjects/41467_2021_27063_Fig4_HTML.png)